Principal Investigator
Gilberto Lopes
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20241278
Clinical Trial Summary
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647